J&J increasingly confident it can manage Stelara cliff, but work remains
强生对喜达诺专利悬崖的应对愈发有信心，但仍有工作要做

Johnson & Johnson executives believe the worst of the biosimilar pressure facing Stelara is behind them, and feel confident enough to predict significant growth through the end of the 2020s.
强生高管认为，喜达诺所面临的生物类似药压力高峰已过去，并有信心预计其将在2020年代末前实现显著增长。